Industrial Strategy for Secure Medicines Manufacturing
From capacity announcements to viable, adaptable national capability.
Executive argument
Domestic manufacturing contributes to security only when facilities, skills, inputs, quality systems and commercial incentives remain operational.
Capability choices
Strategy should distinguish products requiring sovereign assurance, capabilities secured through trusted alliances and commodities suited to diversified sourcing.
Policy instruments
Long-term procurement, challenge funds, regulatory support, shared infrastructure and workforce investment can improve viability.
Conclusion
The test is not facilities announced but the system's ability to supply priority medicines through stress.
Suggested citation
Medicines Security Institute (2026), Industrial Strategy for Secure Medicines Manufacturing, MSI Strategic Papers, Paper 03.
Research and correction standard